TY  - JOUR
AU  - Bragado Domingo, Paloma
AU  - Lorente Pérez, María Del Mar
AU  - Salazar Roa, María
AU  - Velasco Díez, Guillermo
AU  - Tatiana Erazo
AU  - Anna Lopez-Plana
AU  - Pau Munoz-Guardiola
AU  - Patricia Fernandez-Nogueira
AU  - Jose A. García-Martínez
AU  - Gemma Fuster
AU  - Jordi Espadaler
AU  - Javier Hernandez-Losa
AU  - Jose Ramon Bayascas
AU  - Marc Cortal
AU  - Laura Vidal
AU  - Pedro Gascon
AU  - Mariana Gomez-Ferreria
AU  - Jose Alfon
AU  - Carles Domenech
AU  - Jose M. Lizcano
AU  - Jose M. Lizcano
PY  - 2016
DO  - 10.1158/1078-0432.CCR-15-1808
SN  - 1078-0432
UR  - https://hdl.handle.net/20.500.14352/97280
T2  - Clinical Cancer Research
AB  - Purpose: ABTL0812 is a novel first-in-class, small molecule which showed antiproliferative effect on tumor cells in phenotypic assays. Here we describe the mechanism of action of this antitumor drug, which is currently in clinical...
LA  - eng
M2  - 2508
PB  - AMER ASSOC CANCER RESEARCH
KW  - ABTL0812
KW  - AKT/mTOR axis
KW  - cancer
TI  - The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
TY  - journal article
VL  - 22
ER  -